Endocrine Abstracts (2004) 7 P22

The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men

CJ Malkin, PJ Pugh, RD Jones, D Kapoor, KS Channer & TH Jones


Department of Cardiology, Royal Hallamshire Hospital, Sheffield, UK; Academic Unit of Endocrinology, Hormone and Vascular Biology Group, Division of Genomic Medicine, The University of Sheffield, Sheffield, UK; Centre for Diabetes & Endocrinology, Barnsley District General Hospital, Barnsley, UK.


Testosterone has immune-modulating properties and current in-vitro evidence suggests that testosterone may suppress the expression of the pro-inflammatory cytokines Tumour Necrosis Factor (TNF alpha), interleukin (IL)-1 beta and IL-6 and potentiate the expression of the anti-inflammatory cytokine IL-10. We report a randomised single-blind placebo-controlled crossover study of testosterone replacement (Sustanon 100) versus placebo in 27 men (age 62+-9years) with symptomatic androgen deficiency; total testosterone (4.4+-1.2 nmol/L) bioavailable testosterone (2.4+-1.1nmol/L). Compared to placebo, testosterone induced a reduction of TNF alpha (-3.1+-8.3 v 1.3+-5.2 pg/ml, p=0.01), IL-1 beta (-0.14+-0.32 v 0.18+-0.55 pg/ml, p=0.08) and an increase in IL-10 (0.33+-1.8 v -1.1+-3 pg/ml, p=0.01), the reductions of TNF alpha and IL-1 beta were positively correlated (rS = 0.588, p = 0.003). In addition a significant reduction in total cholesterol was recorded with testosterone therapy (-0.25+-0.4 v -0.004+-0.4mmol/L, p=0.04). In conclusion, testosterone replacement shifts the cytokine balance to a state of reduced inflammation and lowers total cholesterol. Twenty of these men had established coronary disease, and since total cholesterol is a cardiovascular risk factor and pro-inflammatory cytokines mediate the development and complications associated with atheromatous plaque, these properties may have particular relevance in men with overt vascular disease.

Article tools

My recent searches

No recent searches.